Cell augmentation strategies for cardiac stem cell therapies
Related Experiment Video
Updated: Nov 15, 2025
Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy
Published on: January 25, 2019
Raquel Cruz-Samperio1, Millie Jordan1, Adam Perriman1
1School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Insights
Emerging cell therapies show promise for treating myocardial infarction (MI) by improving stem cell (SC) viability and engraftment. Novel strategies like cell membrane reengineering and biomimetic scaffolds enhance SC efficacy for cardiac repair post-MI.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Biotechnology
Background:
- Myocardial infarction (MI) is a leading cause of death, imposing significant societal burdens.
- Current MI treatments focus on reperfusion, not myocardial regeneration or functional recovery.
- Regenerative cell therapies (CTs) using stem cells (SCs) show potential but face challenges.
Purpose of the Study:
- To review emerging cell therapies and augmentation strategies for post-MI treatment.
- To highlight advancements in SC-based technologies for cardiac repair.
- To discuss methods improving SC efficacy for myocardial regeneration.
Main Methods:
- Review of current literature on stem cell-based therapies for myocardial infarction.
- Analysis of novel augmentation strategies for cell therapies.
- Focus on cell membrane reengineering, protein immobilization, and scaffold interfaces.
Main Results:
- Identified limitations in current CTs, including poor SC viability, homing, and engraftment.
- Highlighted novel SC-based technologies addressing these limitations.
- Discussed advancements in genetic modification, protein immobilization, and biomimetic scaffolds.
Conclusions:
- Emerging CTs and augmentation strategies are advancing the clinical application of SCs for MI.
- Cell membrane reengineering and biomimetic scaffolds are key to improving SC performance.
- These innovations offer a promising path toward enhanced cardiac regeneration and function recovery post-MI.
Abstract:
Myocardial infarction (MI) has been the primary cause of death in developed countries, resulting in a major psychological and financial burden for society. Current treatments for acute MI are directed toward rapid restoration of perfusion to limit damage to the myocardium, rather than promoting tissue regeneration and subsequent contractile function recovery. Regenerative cell therapies (CTs), in particular those using multipotent stem cells (SCs), are in the spotlight for treatment post-MI. Unfortunately, the efficacy of CTs is somewhat limited by their poor long-term viability, homing, and engraftment to the myocardium. In response, a range of novel SC-based technologies are in development to provide additional cellular modalities, bringing CTs a step closer to the clinic. In this review, the current landscape of emerging CTs and their augmentation strategies for the treatment post-MI are discussed. In doing so, we highlight recent advances in cell membrane reengineering via genetic modifications, recombinant protein immobilization, and the utilization of soft biomimetic scaffold interfaces.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:17Stem Cell Culture